Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus CURRETAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus CURRETAB.
AMEN vs CURRETAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Category C
Category C
Progestin
Progestin